Findings on Diabetic Peripheral Neuropathic Pain at ADA's 84th Scientific Sessions

Lexicon Pharmaceuticals, Inc., a company listed on Nasdaq under the ticker symbol LXRX, has announced that it will present three research posters at the 84th Scientific Sessions of the American Diabetes Association. This event is scheduled to take place from June 21 to June 24, 2024, at the Orange County Convention Center in Orlando, Florida. The presentations will be held on Sunday, June 23, from 12:30 to 1:30 p.m. ET in the Poster Hall (West A-4-B2).

The first presentation is titled "Patient-Reported Burden of Disease in Diabetic Peripheral Neuropathic Pain—Learnings from In-depth Patient Interviews—Substudy of RELIEF-DPN 1." This study, identified as Board No. 484, will be presented by Dr. Linda M. Gaudiani, a Medical Director and President at NorCal Medical Research, and Co-Founder of Braden Diabetes Center in Greenbrae, California.

The second presentation, titled "Impact of Sotagliflozin, a Dual Sodium–Glucose Cotransporter 1/2 Inhibitor, as Add-on to Inadequately Controlled Basal Insulin–Treated Type 2 Diabetes," will be presented by Dr. Julio Rosenstock. He is the Senior Scientific Advisor for Velocity Clinical Research and serves as Director of Velocity’s site at Medical City Dallas, as well as Clinical Professor of Medicine at the University of Texas Southwestern Medical Center. This study is listed as Board No. 924.

The third and final presentation is "Sotagliflozin vs. Empagliflozin or Placebo in Type 2 Diabetes on a DPP-4i +/- Metformin," scheduled as Board No. 917. Dr. Anne L. Peters, a Professor of Medicine at the Keck School of Medicine of USC and the Director of the USC Clinical Diabetes Programs in Los Angeles, California, will deliver this presentation.

Craig Granowitz, Lexicon’s Senior Vice President and Chief Medical Officer, stated that these presentations underscore the company's ongoing commitment to addressing the unmet medical needs within the diabetes community. He expressed gratitude to the individuals with diabetes who shared their personal experiences, shedding light on the significant burdens associated with diabetic peripheral neuropathic pain.

Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon has examined the role of approximately 5,000 genes, identifying over 100 protein targets with high therapeutic potential. The company has successfully launched its medicine INPEFA® (sotagliflozin) in the United States and continues to develop a pipeline of promising drug candidates targeting neuropathic pain, diabetes, metabolism, and other medical conditions.

One of Lexicon’s investigational drugs, LX9211, is an orally administered, selective small molecule inhibitor of adaptor-associated kinase 1 (AAK1). Discovered through Lexicon’s gene science research, LX9211 has shown potential in treating neuropathic pain. The drug has demonstrated effectiveness in preclinical studies and has received Fast Track designation from the U.S. Food and Drug Administration for development in diabetic peripheral neuropathic pain.

Additionally, sotagliflozin, discovered using Lexicon’s gene science approach, is an oral inhibitor targeting sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). It has been studied in various patient populations with heart failure, diabetes, and chronic kidney disease, involving around 20,000 patients in clinical trials.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!